Creative Biolabs is proud to introduce the CAMouse™ VHL strain, which is capable of generating 100% human IgGs with high specificity and affinity post immunization.

Introduction of CAMouse™ VHL Strain

Since 1975, monoclonal antibody has played a vital role in the treatment of diverse human diseases including cancer, autoimmune disorders, viral infections, etc. Various species can be applied to produce monoclonal antibodies. Although human is the best choice of host, it is not ethically acceptable, neither can human be subjected to extreme immunization routines like other animals. One popular animal model, mouse, which is easy to manipulate, has critical defects due to high immunogenicity, resulting in concerns about efficacy loss and severe safety issues. The unique and patented CAMouse™ VHL strain, which allows robust antibody generation in mice with fully human properties, provides a good solution to this challenge.

CAMouse™ VHL strain is specially engineered based on the world-leading transgenic technology with unparalleled efficiency. The entire human IgG genes (including heavy/light chain constant regions) were introduced into endogenous Ig gene-silenced mouse germline. Rodent regulatory segments were also introduced to ensure antibody diversification. After immunization, a large pool of full-length human IgGs will be obtained. Of note, a unique “switch” strategy has been used to avoid incompatibility during B cell development and maturation. Therefore, the resulting antibody repertoire will be completely human sequence, while immune system performance will not be compromised in this process.

Attractive Features of the CAMouse™ VHL Strain Antibody Discovery Service

• Fully human antibody: CAMouse™ VHL strain is capable of producing significant levels of fully human antibodies with a diverse adult-like repertoire against certain antigen.
• Superior diversity: The transgenic design and technology used for CAMouse™ VHL strain allow potent antibody gene rearrangement, class switching, and somatic hypermutation, which is the foundation for yielding diversified antibody pools.
• Robust discovery technologies: Incorporated with versatile antibody discovery platforms, we provide flexible, one-stop antibody development service package using hybridoma, phage display, B cell sorting, etc.
• Fast turnaround time: Without the need to perform tedious antibody humanization and affinity maturation in vitro, antibodies produced from the CAMouse™ VHL strain can save your valuable time and make your project more competitive.

Ph.D level scientists at Creative Biolabs are ready to serve each specific need from our clients and we are more than pleased to tailor specifically a la carte service packages to better suit your pipeline. Please feel free to contact us for more details.

Related Sections

Please note: we only produce antibodies for research purposes. Our products and services cannot be used directly on humans.